'A Breakthrough in Saving Lives': Cizzle's Blood Test for Lung Cancer Accredited for Clinical Use in US

'A breakthrough in saving lives': Cizzle's blood test for lung cancer accredited for clinical use in US

York-based Cizzle Biotechnology Holdings has reported on a “landmark” half year in which its blood test for lung cancer was successfully accredited for clinical use in the US, the world’s largest diagnostics market.

Cizzle Biotechnology Moves CIZ1B Lung Cancer Test Into Commercialisation

Cizzle Biotechnology has moved its CIZ1B biomarker blood test into commercialisation after securing US clinical accreditation, with the company now focused on expanding access across North America and progressing opportunities in the UK and other international markets.